The ubiquitin-proteasome system regulates many essential cellular processes including cell division. The recent development of cancer drugs that inhibit the proteasome suggests that the ubiquitin-proteasome system may provide many new therapeutic targets. The goal of this project is to develop new chemical inhibitors of the ubiquitin-proteasome system, and to understand how this pathway regulates cell division. We first plan to characterize novel small molecule inhibitors of the Anaphase-Promoting Complex (APC), a ubiquitin ligase that is essential for cell division. APC inhibitors may be useful for the treatment of cancer, because they may inhibit cell division or sensitize cells to antimitotic drugs such as taxol. Additionally, APC inhibitors may be useful for the treatment of diseases that involve axonal injury, because the APC negatively regulates axon growth. Our studies of these small molecules will also provide important new insights into how the APC is regulated by activator proteins. Another goal of our studies is to characterize ubistatins, compounds that prevent ubiquitin- dependent proteolysis by binding to ubiquitin chains. However, the mechanism of ubiquitin chain binding remains unclear, and we plan to synthesize new ubistatin derivatives that will allow us to determine the structure of ubistatins bound to ubiquitin chains. The structural information will enable us to synthesize more potent and perhaps more cell-permeable versions of ubistatins, enhancing the utility of these compounds to investigators in the field, and accelerating the development of ubiquitin-binding compounds as drug candidates. A third goal of our research program is to understand how ubiquitinated substrates are recognized for degradation by the proteasome. It has been assumed that a specific type of ubiquitin chain (linked through lysine-48 of ubiquitin) is required for degradation by the proteasome. Our studies of ubiquitinated cyclin B1 suggest that other types of ubiquitin linkages may be sufficient to target the protein for degradation. We therefore plan to determine the types of ubiquitination that are required for degradation of cyclin B1 by purified proteasomes and in complex cell extracts. These studies are critical for understanding how small molecule inhibitors of ubiquitination and ubiquitin chain recognition may perturb degradation. Finally, we want to understand how the localization of substrates affects their degradation by the ubiquitin-proteasome system. We have identified a novel sequence element in cyclin B1 that recruits the protein to chromatin during mitosis. We plan to identify the protein that recruits cyclin B1 to chromatin, and to determine the functional consequences of cyclin B1 association with chromatin. Together these studies will provide new chemical tools for studying the ubiquitin-proteasome pathway, and will help us understand how a critical substrate of this pathway, cyclin B1, is regulated during the cell cycle.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM066492-08
Application #
7796721
Study Section
Nuclear Dynamics and Transport (NDT)
Program Officer
Hamlet, Michelle R
Project Start
2002-05-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$360,781
Indirect Cost
Name
Harvard University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Boselli, Monica; Lee, Byung-Hoon; Robert, Jessica et al. (2017) An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J Biol Chem 292:19209-19225
Lee, Byung-Hoon; Lu, Ying; Prado, Miguel A et al. (2016) USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites. Nature 532:398-401
Lub, Susanne; Maes, Anke; Maes, Ken et al. (2016) Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget 7:4062-76
Lu, Ying; Lee, Byung-hoon; King, Randall W et al. (2015) Substrate degradation by the proteasome: a single-molecule kinetic analysis. Science 348:1250834
de Lange, Job; Faramarz, Atiq; Oostra, Anneke B et al. (2015) Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. Nat Commun 6:8399
King, Randall W; Finley, Daniel (2014) Sculpting the proteome with small molecules. Nat Chem Biol 10:870-4
Sackton, Katharine L; Dimova, Nevena; Zeng, Xing et al. (2014) Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514:646-9
Pfaff, Kathleen L; King, Randall W (2013) Determinants of human cyclin B1 association with mitotic chromosomes. PLoS One 8:e59169
Lim, Hui-Jun; Dimova, Nevena V; Tan, Meng-Kwang Marcus et al. (2013) The G2/M regulator histone demethylase PHF8 is targeted for degradation by the anaphase-promoting complex containing CDC20. Mol Cell Biol 33:4166-80
Sigoillot, Frederic D; Lyman, Susan; Huckins, Jeremy F et al. (2012) A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens. Nat Methods 9:363-6

Showing the most recent 10 out of 30 publications